TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9809179
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both concentric and eccentric training
Study: 2676911
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of 18,000 IE retinol, 70 mg L‐cystine, and 7000 mg gelatin
Study: 365487
Drug: Amikacin (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin (375 mg/d three times i.m.)
Study: 365487
Drug: Gentamicin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (80 mg/d three times i.m.)
Study: 30114561
Drug: Tinzaparin (4500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin (4500 IU daily until 37 gestational weeks)
Study: 25197922
Drug: Nebulized 9-mg
Normalized name: sodium chloride 9 MG/ML [Hydra-Neb]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized 9-mg sodium hyaluronate nasal washes plus saline solution
Study: 25197922
Drug: Saline alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline alone (5 mL)
Study: 17396441
Drug: 5 MU/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 MU/m2 IFN-alpha therapy for 6 months
Study: 17396441
Drug: 10 MU/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 MU/m2 IFN-alpha therapy for 6 months
Study: 15618257
Drug: Medical abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical abortion (600 mg mifepristone followed by 1 mg gemeprost)
Study: 11860971
Drug: Prophylactic laser
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic laser therapy (16 eyes)
Study: 11860971
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (19 eyes)
Study: 6112842
Drug: Active antiparkinson
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antiparkinson (AP) medication
Study: 30716938
Drug: Information treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information treatment on biodegradable mulches
Study: 28944357
Drug: Implant-supported crown
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported crown
Study: 26755507
Drug: Volasertib 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib 300 mg by intravenous infusion every 3 weeks
Study: 26755507
Drug: Chemotherapy (investigator's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (investigator's choice of single-agent, nonplatinum, cytotoxic chemotherapy)
Study: 15751665
Drug: Heparin during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin during CPB in patients with postoperative SIRS (Group B)
Study: 9858352
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin plus amoxicillin 2 g and probenecid 500 mg orally three times daily for 10 days
Study: 1454956
Drug: Experimental Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Group (exposed to a distinctive stimulus before each infusion of chemotherapy)
Study: 6230999
Drug: Topical 1.5%
Normalized name: phenol topical 1.5% topical liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1.5% erythromycin solution
Study: 6230999
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% clindamycin phosphate solution
Study: 26715213
Drug: CYP2B6 983TC/CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2B6 983TC/CC genotype
Study: 26715213
Drug: C12 between
Normalized name: C12:0
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C12 between 0.47 and 0.76 mg/L
Study: 23609378
Drug: Typical antipsychotics
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical antipsychotics (TAs)
Study: 23609378
Drug: Nonclozapine atypical
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonclozapine atypical antipsychotics (AAs)
Study: 18235202
Drug: Ganciclovir 50
Normalized name: ganciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir 50 mg/ml
Study: 17000819
Drug: Standard intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intraoperative and postoperative analgesic regimen (morphine sulfate, diclofenac, dextropropoxyphene hydrochloride + acetaminophen prn)
Study: 17000819
Drug: Continuous paravertebral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous paravertebral block (for 48 h) and acetaminophen and parecoxib (followed by celecoxib up to 5 days)
Study: 14582587
Drug: Brief information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief information + relaxation therapy (BI + RT)
Study: 27340112
Drug: Escitalopram +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram + internet-delivered cognitive-behavioural therapy (ICBT)
Study: 20595543
Drug: β1‐adrenoreceptor blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: β1‐adrenoreceptor blocker (atenolol; βB) 0.2 mg/kg
Study: 18032083
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) with insulin lispro
Study: 12402765
Drug: Avelox (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelox (400 mg/day for 10 days)
Study: 12402765
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg twice a day for 10 days)
Study: 2980291
Drug: CR-capsules (controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR-capsules (controlled release)
Study: 2980291
Drug: Unixan tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unixan tablets
Study: 25982544
Drug: simvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin (80 mg) once daily
Study: 21095483
Drug: placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once daily
Study: 21515905
Drug: Mental rehearsal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental rehearsal of upper limb movements during 45-min supervised sessions three times a week and structured independent sessions twice a week
Study: 19368503
Drug: Selenium supplements
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplements (200 microg of selenomethionine)
Study: 16886974
Drug: Tiagabine (TGB)
DrugBank: Tiagabine (DB00906)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiagabine (TGB) 20-30 mg/day
Study: 16886974
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 400-800 mg/day
Study: 16886974
Drug: No-drug group
Normalized name: Heparin group antithrombotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-drug group (untreated patients)
Study: 17307536
Drug: Early inhaled
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early inhaled nitric oxide (iNO) therapy
Study: 11317659
Drug: Intensive blood-glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood-glucose control with metformin (n = 342)
Study: 11317659
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy primarily with diet (n = 411)
Study: 8107555
Drug: Acetaminophen administered
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen administered intragastrically in a single dose of 1.0 g.
Study: 31926063
Drug: BioBase mobile
Normalized name: Bioease Pain Relieving Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioBase mobile app and paired wearable device (BioBeam) used daily for 4 weeks
Study: 23817682
Drug: Low-dose CT-guided
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT-guided biopsy (group B: 120 kv; 10 mA; thickness, 2.0 mm; pitch, 23 mm/rot)
Study: 22045831
Drug: N-acetylcysteine (NAC;
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC; 50 mg/kg by 4 hours followed by 100 mg/kg/d for 48 hours diluted in 5% glucose) and deferoxamine (DFX; at a single dose of 1000 mg diluted in 5% glucose)
Study: 19745592
Drug: Bendamustine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine (200 mg flat dose on days 1 + 2, repeated at day 28 or upon recovery of neutrophils)
Study: 3416618
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered melatonin
Study: 30717691
Drug: Lower range
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower range group (LRG) 0.8‐1.4 mmol/L or 2.5‐4.3 mg/dL
Study: 30717691
Drug: Higher range
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher range group (HRG) 1.8‐2.4 mmol/L or 5.6‐7.4 mg/dL
Study: 21975926
Drug: Platycodi radix
Normalized name: Valerianae radix
DrugBank: Platycodon grandiflorus root (DB14347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platycodi radix extract standardized to 414 mg of platycodin D
Study: 12661753
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg once daily for 16 weeks
Study: 3928508
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Voltaren (diclofenac-sodium) before surgery and then 50 mg 3 times a day for 5 days
Study: 3928508
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination tablets (acetylsalicylic acid 500 mg, caffeine 50 mg, aprobarbital 20 mg, codeine phosphate 10 mg) in the highest recommended dose, 2 tablets when needed at most 3 times a day
Study: 26639943
Drug: Luseogliflozin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin 2.5 mg once daily with normal-carbohydrate diet (NCD)
Study: 26639943
Drug: Luseogliflozin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin 2.5 mg once daily with low-carbohydrate diet (LCD)
Study: 24581393
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by external beam radiotherapy (EBRT) with concomitant cisplatin (Arm A)
Study: 24581393
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by EBRT with concomitant cisplatin plus brachytherapy boost (Arm B)
Study: 24581393
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by EBRT with concomitant cisplatin (Arm A)
Study: 22933542
Drug: Vitamin D(3),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3), 50,000 IU monthly (n = 102)
Study: 11576201
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (300 to 1200 mg per day)
Study: 11576201
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (serum levels >50 microg/mL)
Study: 9819872
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate 5 mg-patches
Study: 7657848
Drug: Enalapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (2.5 mg twice daily)
Study: 28244635
Drug: linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 5 mg once daily for 26 weeks
Study: 26135706
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone 1000 mg once a day for 3 days
Study: 26135706
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone 1000 mg once a day for 3 days
Study: 23880625
Drug: B lactis
Approvals — FDA: no, EMA: no, PMDA: no
Description: B lactis + GOS/FOS (10 colony-forming units/g + 0.4 g/100 mL)
Study: 23880625
Drug: B lactis
Approvals — FDA: no, EMA: no, PMDA: no
Description: B lactis (10⁷ colony-forming units/g)
Study: 15956071
Drug: Iron-gluconate 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-gluconate 62.5 mg
Study: 15956071
Drug: Iron-gluconate 125
Normalized name: Iron(2+) gluconate (1:2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-gluconate 125 mg
Study: 15956071
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg iron-gluconate)
Study: 15956071
Drug: Iron-gluconate (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-gluconate (both doses)
Study: 7576328
Drug: Improved STD
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved STD treatment services
Study: 7576328
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard STD treatment)
Study: 2206015
Drug: GM1 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GM1 treatment
Study: 6989464
Drug: Therapy with
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy with platelet antiaggregants
Study: 31431370
Drug: Hyperthermia (HT)
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermia (HT) combined with radiation treatment (RT)
Study: 31669450
Drug: Modified directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified directly observed therapy (mDOT)
Study: 21324181
Drug: Sequential behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential behaviour tailoring condition
Study: 15581383
Drug: Zolmitriptan 5
Normalized name: zolmitriptan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan 5 mg ODT
Study: 11307043
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg L‐Dopa
Study: 2728828
Drug: 0.03 mg
Normalized name: biotin 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg buprenorphine
Study: 2728828
Drug: 0.045 mg
Normalized name: biotin 0.045 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.045 mg buprenorphine
Study: 10858715
Drug: 4% PRO
Normalized name: Stanimax 2.84% Pro Perio Mouthwash Dental Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% PRO 2000 gel
Study: 10858715
Drug: 0.5% PRO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% PRO 2000 gel
Study: 12614254
Drug: Testim 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testim 100 mg/day
Study: 12614254
Drug: Testim 50
Normalized name: Testim 50 MG per 5 GM Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testim 50 mg/day
Study: 10568572
Drug: Campath‐1H monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campath‐1H monoclonal antibody treatment (5-day pulse)
Study: 9005794
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg intravenously twice a day for 4 to 6 days, then orally for 4 to 6 days)
Study: 9005794
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (broad spectrum antibiotics such as amplox, gentamicin, and 3rd generation cephalosporins)
Study: 30745118
Drug: Radiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy combined with long-term androgen deprivation therapy
Study: 30745118
Drug: Chemotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy or next-generation hormone therapies
Study: 23392919
Drug: On and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: On and off medication states (for VIDEO group)
Study: 22134562
Drug: CLNP 1.2%-BPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLNP 1.2%-BPO 3% gel
Study: 22134562
Drug: CLNP 1.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLNP 1.2% gel
Study: 22134562
Drug: BPO 3%
Normalized name: BPO 3% Foaming Cloth
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPO 3% gel
Study: 19549737
Drug: NaCl supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl supplementation (100 mmol/day) during telmisartan treatment with or without HCT
Study: 19549737
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during telmisartan treatment with or without HCT
Study: 15085888
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day of docosahexaenoic acid (DHA) supplementation
Study: 15887725
Drug: Topical itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical itraconazole (1%)
Study: 15887725
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and systemic itraconazole
Study: 9088580
Drug: Transdermal nicotine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nicotine, 15 mg/day
Study: 9088580
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray, 24-1 mg doses/day
Study: 9088580
Drug: Placebo nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nicotine nasal spray, 24 doses/day
Study: 7680306
Drug: Chemotherapy (COPP/ABVD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (COPP/ABVD scheme, with or without mediastinal irradiation)
Study: 3749604
Drug: Aceglutamide aluminum
Normalized name: aceglutamide aluminum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceglutamide aluminum (N‐acetyl‐L‐glutamine aluminum complex) administered in multiple daily doses (total of 3290 mg over 14 days)
Study: 26862079
Drug: Information about
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information about treatment for alcohol abuse
Study: 26862079
Drug: Information about
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information about treatment for alcohol dependence
Study: 20356492
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human tissue-type plasminogen activator (rt-PA) 50 mg
Study: 20356492
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human tissue-type plasminogen activator (rt-PA) 100 mg
Study: 15997603
Drug: Equivalent hours
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent hours of treatment in the same intensive behavioral rehabilitation program
Study: 12764404
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs (group DT; 100 patients)
Study: 12764404
Drug: ACE-I/ARB treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-I/ARB treatment in DT group
Study: 10334417
Drug: Prestudy medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prestudy medication with calcium antagonists.
Study: 1758253
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) analgesia
Study: 25891440
Drug: Vilazodone 20
Normalized name: vilazodone 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilazodone 20 mg/day
Study: 22106941
Drug: Vilazodone 40
Normalized name: vilazodone 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilazodone 40 mg/day
Study: 30044247
Drug: Vilazodone (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilazodone (combined 20 and 40 mg/day)
Study: 19694628
Drug: venlafaxine-quetiapine (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine-quetiapine (375 mg/day, 600 mg/day)
Study: 19694628
Drug: imipramine (plasma-levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: imipramine (plasma-levels 200-300 microg/l)
Study: 17907276
Drug: Antidementia drug
Normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidementia drug treatment
Study: 12975222
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors (ChEIs)
Study: 12237200
Drug: Opioid blockade
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid blockade (8 mg naloxone i.v.)
Study: 10971304
Drug: Pseudoephedrine (PSE)
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pseudoephedrine (PSE) 180 mg
Study: 1569238
Drug: Betaxolol 5
Normalized name: betaxolol 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 5 mg once daily
Study: 1569238
Drug: Betaxolol 10
Normalized name: betaxolol 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 10 mg once daily
Study: 1569238
Drug: Betaxolol 20
Normalized name: betaxolol 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 20 mg once daily
Study: 2997314
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran diet (normal daily intake + 78 gm wheat bran per day)
Study: 2997314
Drug: Cellulose diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellulose diet (normal daily intake + 30 gm cellulose per day)
Study: 2997314
Drug: Baseline diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline diet (normal daily intake)
Study: 30203747
Drug: Intravenous nutrition
Normalized name: Intravenous nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nutrition therapy for observation group infants
Study: 19844199
Drug: Half doses
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half doses of PEG-ES and 12 tablets of 12 mg senna (HDG)
Study: 19844199
Drug: High-dose senna
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose senna (SG)
Study: 16227727
Drug: Other medications
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other medications for ocular complications or pain relief
Study: 3886998
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific therapy